Local Renin Angiotensin Aldosterone Systems and Cardiovascular Diseases

Medical Clinics of North America

Volumn 101, Issue 1, 2017, Pages 117-127

  De Mello, Walmor C ^a  

^a UNIVERSITY OF PUERTO RICO MEDICAL SCIENCES CAMPUS   (Puerto Rico)

Author keywords

Cardiovascular diseases; Expression; Internalization; Local renin angiotensin

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSINOGEN; DIPEPTIDYL CARBOXYPEPTIDASE; MINERALOCORTICOID RECEPTOR; RENIN; ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR; G PROTEIN COUPLED RECEPTOR; ONCOPROTEIN; PROTO-ONCOGENE PROTEINS C-MAS-1;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; DISEASE ASSOCIATION; DNA METHYLATION; EPIGENETICS; GENETIC ASSOCIATION; HEART FAILURE; HEART VENTRICLE HYPERTROPHY; HISTONE MODIFICATION; HUMAN; KIDNEY PARENCHYMA; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; VASCULAR SMOOTH MUSCLE; CELL COMMUNICATION; GENETIC EPIGENESIS; GENETICS; KIDNEY; METABOLISM;

ANGIOTENSIN II; CARDIOVASCULAR DISEASES; CELL COMMUNICATION; EPIGENESIS, GENETIC; HUMANS; KIDNEY; MUSCLE, SMOOTH, VASCULAR; PEPTIDYL-DIPEPTIDASE A; PROTO-ONCOGENE PROTEINS; RECEPTORS, ANGIOTENSIN; RECEPTORS, G-PROTEIN-COUPLED; RENIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 84996761489     PISSN: 00257125     EISSN: 15579859     Source Type: Journal    
DOI: 10.1016/j.mcna.2016.08.017     Document Type: Review

References (62)

1. 1 Pfeffer, M.A., Pfeffer, J.M., Frohlich, E.D., Pumping ability of the hypertrophying left ventricle of the spontaneously hypertensive rat. Circ Res 38 (1976), 423–429.
2. 2 Pfeffer, M.A., Pfeffer, J.M., Braunwald, E., Influence of chronic captopril therapy on the infracted left ventricle of the rat. Circ Res 57 (1985), 84–95.
3. 3 Pfeffer, J.M., Pfeffer, M.A., Mirsky, I., et al. Regression of left ventricular hypertrophy and prevention of left ventricular dysfunction by captopril in the spontaneously hypertensive rat. Proc Natl Acad Sci U S A 79 (1982), 3310–3314.
4. 4 Pfeffer, M.A., Braunwald, E., Moye, L.A., et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial. N Engl J Med 327 (1992), 669–677.
5. 5 Pfeffer, M.A., Frohlich, E.D., Improvements in clinical outcomes with the use of angiotensin converting enzyme inhibitors. Cross-fertilization between clinical investigations. Am J Physiol Heart Circ Physiol 291 (2006), H2021–H2025.
6. 6 Veterans Administration Cooperative Study Group on Antihypertensive Agents, Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressure averaging 115 through 129 mm Hg. JAMA 202 (1967), 1028–1034.
7. 7 Veterans Administration Cooperative Study Group on Antihypertensive Agents, Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA 213 (1970), 1143–1152.
8. 8 Frohlich, E.D., Risk mechanisms in hypertensive heart disease. Hypertension 34 (1999), 782–789.
9. 9 Jin, Y., Han, H.C., Lindsey, M.L., ACE inhibitors to block MMP-9 activity: new functions for old inhibitors. J Mol Cell Cardiol 43:6 (2007), 664–666.
10. 10 Donoghue, M., Hsieh, F., Baronas, E., et al. Novel angiotensin converting enzyme related carboxypeptidase (ACE2) converts angiotensin I to angiotensin (1-9). Circ Res 87 (2000), E1–E9.
11. 11 Tipnis, S.R., Hooper, N.M., Hyde, R., et al. A human homolog of angiotensin converting enzyme. Cloning and functional expression as a captopril insensitive carboxypeptidase. J Biol Chem 275 (2000), 33238–33243.
12. 12 Ferrario, C.M., Chappell, M.C., Tallant, E.A., et al. Counterregulatory actions of angiotensin (1-7). Hypertension 30 (1997), 535–541.
13. 13 Crackower, M.A., Sarao, R., Oudit, G.Y., et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 417:6891 (2002), 822–828.
14. 14 Ferrario, C.M., Trask, A.J., Jessup, J.A., Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1-7) in regulation of cardiovascular function. Am J Physiol Heart Circ Physiol 289 (2005), H2281–H2290.
15. 15 De Mello, W.C., Ferrario, C.M., Jessup, J.A., Beneficial versus harmful effects of Angiotensin (1-7) on impulse propagation and cardiac arrhythmias in the failing heart. J Renin Angiotensin Aldosterone Syst 8 (2007), 74–80.
16. 16 De Mello, W.C., Angiotensin (1–7) re-establishes impulse conduction in cardiac muscle during ischaemia-reperfusion. The role of the sodium pump. J Renin Angiotensin Aldosterone Syst 5:4 (2004), 203–208.
17. 17 Zisman, L.S., Keller, R.S., Weaver, B., et al. Increased angiotensin (1-7) forming activity in failing human heart ventricles: evidence for upregulation of the angiotensin converting enzyme homolog, ACE2. Circulation 108 (2003), 1707–1712.
18. 18 Santos, R.A., Ferreira, A.J., Simões, E., Recent advances in the angiotensin-converting enzyme 2-angiotensin (1-7)-Mas axis. Exp Physiol 93:5 (2008), 519–527.
19. 19 De Mello, W.C., Cell swelling, impulse conduction, and cardiac arrhythmias in the failing heart. Opposite effects of angiotensin II and angiotensin (1-7) on cell volume regulation. Mol Cell Biochem 330:1–2 (2009), 211–217.
20. 20 Rentzsch, B., Todiras, M., Iliescu, R., et al. Transgenic angiotensin-converting enzyme 2 overexpression in vessels of SHRSP rats reduces blood pressure and improves endothelial function. Hypertension 52:5 (2008), 967–973.
21. 21 De Mello, W.C., Frohlich, E.D., On the local cardiac renin angiotensin system. Basic and clinical implications. Peptides 32 (2011), 1774–1779.
22. 22 Kurdi, M., De Mello, W.C., Booz, G.W., Working outside the system: an update on the unconventional behavior of the renin-angiotensin system components. Int J Biochem Cell Biol 37 (2005), 1357–1367.
23. 23 Danser, A.H., van Kats, J.P., Admiraal, P.J., et al. Cardiac renin and angiotensins; uptake from plasma versus in situ synthesis. Hypertension 24 (1994), 37–48.
24. 24 de Lannoy, L.M., Danser, A.H., Bouhuizen, A.M., et al. Localization and production of angiotensin II in the isolated perfused rat heart. Hypertension 31 (1998), 1111–1117.
25. 25 Serneri, G.G., Boddi, M., Cecione, I., et al. Cardiac angiotensin II formation in the clinical course of heart failure and its relationship with left ventricular function. Circ Res 88 (2001), 961–968.
26. 26 Reudelhuber, T.L., Bernstein, K.E., Delafontaine, P., Is angiotensin II a direct mediator of left ventricular hypertrophy?. Hypertension 49 (2007), 1196–1201.
27. 27 Mazzolai, L., Nussberger, J., Aubert, J.F., et al. Blood pressure-independent cardiac hypertrophy induced by locally activated renin angiotensin system. Hypertension 31 (1998), 1324–1330.
28. 28 De Mello, W., Rivera, M., Rabell, A., et al. Aliskiren, at low doses, reduces the electrical remodeling in the heart of the TGR (mRen2)27 rat independently of blood pressure. J Renin Angiotensin Aldosterone Syst 14:1 (2013), 23–33.
29. 29 Clausmeyer, S., Reinecke, A., Farrenkopf, R., et al. Tissue-specific expression of a rat renin transcript lacking the coding sequence for the prefragment and its stimulation by myocardial infarction. Endocrinology 141:8 (2000), 2963–2970.
30. 30 Peters, J., Cytosolic (pro) renin and the matter of intracellular renin actions. Front Biosci (Schol Ed) 5 (2013), 198–205.
31. 31 Abadir, P.M., Walston, J.D., Carey, R.M., Subcellular characteristics of functional intracellular renin-angiotensin systems. Peptides 38:2 (2012), 437–445.
32. 32 De Mello, W.C., Intracellular renin alters the electrical properties of the intact heart ventricle of adult Sprague Dawley rats. Regul Pept 181 (2013), 45–49.
33. 33 De Mello, W.C., Danser, A.H.J., Angiotensin II and the heart: on the intracrine renin-angiotensin system. Hypertension 35:6 (2000), 1183–1188.
34. 34 De Mello, W.C., Cardiac arrhythmias: the possible role of the renin-angiotensin system. J Mol Med (Berl) 79:2–3 (2001), 103–108.
35. 35 De Mello, W.C., Is an intracellular renin-angiotensin system involved in control of cell communication in heart?. J Cardiovasc Pharmacol 23:4 (1994), 640–646.
36. 36 Shefe, J.H., Menk, M., Reinemund, J., et al. A novel signal transduction cascade involving direct physical interaction of the renin/prorenin receptor with the transcription factor promyelocytic zinc finger protein. Circ Res 99 (2006), 1355–1366.
37. 37 De Mello, W.C., On the pathophysiological implications of an intracellular renin receptor. Circ Res 99 (2006), 1285–1286.
38. 38 De Mello, W.C., Chemical communication between heart cells is disrupted by intracellular renin and angiotensin II: implications for heart development and disease. Front Endocrinol (Lausanne), 6, 2015, 72.
39. 39 De Mello, W.C., Aldosterone disrupts the intercellular flow of glucose in cardiac muscle. Front Endocrinol (Lausanne), 6, 2015, 185.
40. 40 De Mello, W.C., Gerena, Y., Further studies on the effects of intracrine and extracellular angiotensin II on the regulation of heart cell volume. On the influence of aldosterone and spironolactone. Regul Pept 165 (2010), 200–205.
41. 41 Dzau, V.J., Vascular renin-angiotensin: a possible autocrine or paracrine system in control of vascular function. J Cardiovasc Pharmacol 6:Suppl 2 (1984), S377–S382.
42. 42 Inagami, T., Mizuno, K., Nakamuro, M., et al. The renin angiotensin system: an overview of its intracellular action. Cardiovasc Drugs Ther 2 (1988), 453–456.
43. 43 Nguyen, G., Muller, D.N., The biology of the (pro)renin receptor. J Am Soc Nephrol 21:1 (2010), 18–23.
44. 44 Kurauchi-Mito, A., Ichihara, A., Bokuda, K., et al. Significant roles of the (pro)renin receptor in integrity of vascular smooth muscle cells. Hypertens Res 37:9 (2014), 830–835.
45. 45 De Mello, W.C., Intracellular angiotensin II increases the total potassium current and the resting potential of arterial myocytes from vascular resistance vessels of the rat. Physiological and pathological implications. J Am Soc Hypertens 7:3 (2013), 192–197.
46. 46 De Mello, W.C., Intracellular angiotensin II as a regulator of muscle tone in vascular resistance vessels. Pathophysiological implications. Peptides 78 (2016), 87–90.
47. 47 Nelson, M.T., Quayle, J.M., Physiological roles and properties of potassium channels in arterial smooth muscle. Am J Physiol 268 (1995), C799–C822.
48. 48 Gelband, C.H., Hume, J.R., [CaP]1 inhibition of K+ channels in canine renal artery. Novel mechanism for agonist induced membrane depolarization. Circ Res 77 (1995), 121–130.
49. 49 Navar, L.G., Kobori, H., Prieto, M.C., et al. Intrarenal renin-angiotensin system in hypertension. Hypertension 57 (2011), 355–362.
50. 50 Kobori, H., Nangaku, M., Navar, L.G., et al. The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev 59:3 (2007), 251–287.
51. 51 Lu, X., Roksnoer, L.C., Danser, A.H., The intrarenal renin-angiotensin system: does it exist? Implications from a recent study in renal angiotensin-converting enzyme knockout mice. Nephrol Dial Transplant 28:12 (2013), 2977–2982.
52. 52 Crowley, S.D., Gurley, S.B., Herrera, M.J., et al. Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney. Proc Natl Acad Sci U S A 103:47 (2006), 17985–17990.
53. 53 Gonzalez-Villalobos, R.A., Janjoulia, T., Fletcher, N.K., et al. The absence of intrarenal ACE protects against hypertension. J Clin Invest 123:5 (2013), 2011–2023.
54. 54 Chappell, M.C., Non classical renin-angiotensin system and renal function. Compr Physiol 2:4 (2012), 2733–2752.
55. 55 Kobori, H., Harrison-Bernard, L.M., Navar, L.G., Expression of angiotensinogen mRNA and protein in angiotensin II-dependent hypertension. J Am Soc Nephrol 12 (2001), 431–439.
56. 56 Bogdarina, I., Welham, S., King, P.J., et al. Epigenetic modification of the renin angiotensin system to the fetal programming of hypertension. Circ Res, 100, 2007, 520.
57. 57 Nührenberg, T., Gilsbach, R., Preissl, S., et al. Epigenetics in cardiac development, function, and disease. Cell Tissue Res 356:3 (2014), 585–600.
58. 58 Barker, D.J., Osmond, C., Infant mortality, childhood nutrition, and ischemic heart disease in England and Wales. Lancet 1 (1986), 1077–1081.
59. 59 Lackland, D.T., Egan, B.M., Syddall, H.E., et al. Associations between birth weight and antihypertensive medication in black and white Medicaid recipients. Hypertension 39 (2002), 179–183.
60. 60 Alexander, B.T., Dasinger, J.H., Intapad, S., Fetal programming and cardiovascular pathology. Compr Physiol 5:2 (2015), 997–1025.
61. 61 Alexander, M.R., Owens, G.K., Owens epigenetic control of smooth muscle cell differentiation and phenotypic switching in vascular development and disease. Annu Rev Physiol 74 (2012), 13–40.
62. 62 Cook, J.L., Re, R.N., Lessons from in vitro studies and a related intracellular angiotensin II transgenic mouse model. Am J Physiol Regul Integr Comp Physiol 302 (2012), R482–R493.